SurModics, Inc.

321 articles about SurModics, Inc.

• Surmodics to Participate in the Jefferies Healthcare Conference on June 8

  5/25/2023

  Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced that management will participate in the Jefferies Healthcare Conference, which is being held in New York, NY, from June 7-9, 2023.

• Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

  4/26/2023

  Surmodics, Inc. today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023.

• Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System

  4/20/2023

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounce™ Thrombectomy System Retrospective Registry.

• Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26

  4/19/2023

  Surmodics, Inc. today announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26.

• Surmodics Announces Successful First Patient Use of Sublime™ Radial Access Microcatheter Designed for the Periphery

  4/19/2023

  Sublime Radial Access Platform to include the industry’s first suite of torqueable peripheral microcatheters, designed for navigating tortuosity and crossing complex lesions and available for both transradial and transfemoral procedures.

• Surmodics to Participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20

  4/11/2023

  Surmodics, Inc. today announced that management will participate in the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023.

• Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated Balloon

  3/28/2023

  Surmodics, Inc. (NASDAQ:SRDX) today announced that it has received formal feedback from the Food and Drug Administration (FDA; the Agency) related to its proposed approach to submit an amended premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB).

• Surmodics to Participate in Upcoming Investor Conferences in March

  3/8/2023

  Surmodics, Inc. today announced that management will participate in the following upcoming investor conferences.

• Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

  2/6/2023

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2022, and updated its financial outlook for its fiscal year ending September 30, 2023.

• Surmodics to Host Virtual Annual Meeting of Shareholders - January 31, 2023

  1/31/2023

  Surmodics, Inc. will hold its Annual Meeting of Shareholders on Thursday, February 9, at 4 p.m. CT (5 p.m. ET), as a virtual meeting.

• Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6

  1/26/2023

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2023 financial results will be released after the market closes on Monday, February 6.

• Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference

  1/19/2023

  Surmodics, Inc. today announced that the differentiated capabilities of its crystalline drug release (CDR) platform for sirolimus-coated balloons (SCBs) were discussed in connection with 12-month data from the Company’s SWING trial at the 35th annual International Symposium on Endovascular Therapy (ISET) in Miami, Florida.

• Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon

  1/19/2023

  Surmodics, Inc. today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB).

• Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18

  1/16/2023

  Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 12-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB).

• Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

  11/17/2022

  Surmodics, Inc. today announced that 12-month data from the SWING Trial, a first-in-human study of the Company’s Sundance™ Sirolimus drug-coated balloon (DCB) was presented at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.

• Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

  11/11/2022

  Surmodics, Inc. announced today that Professor Ramon Varcoe will present 12-month data from the SWING Trial, a first-in-human study of the safety and efficacy of the Sundance™ Sirolimus Drug-Coated Balloon (DCB).

• Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance

  11/9/2022

  Surmodics, Inc. today reported financial results for its fourth quarter and fiscal year ended September 30, 2022, and introduced its financial outlook for the fiscal year ending September 30, 2023.

• 24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference

  11/2/2022

  Surmodics, Inc. today announced that 24-month data from its TRANSCEND clinical trial has been presented at the Vascular InterVentional Advances (VIVA) annual conference in Las Vegas.

• Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th

  10/28/2022

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Wednesday, November 9th.

• Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022

  10/26/2022

  Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022.